Recent Trends in RSV Immunoprophylaxis: Clinical Implications for the Infant

Santiago Acero-Bedoya; Phillip S. Wozniak; Pablo J. Sánchez; Octavio Ramilo; Asuncion Mejias

doi:10.1055/s-0039-1691803

American Journal of Perinatology, Table of Contents

Am J Perinatol 2019; 36(S 02): S63-S67
DOI: 10.1055/s-0039-1691803

Review Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Recent Trends in RSV Immunoprophylaxis: Clinical Implications for the Infant

Authors

Santiago Acero-Bedoya

¹Center for Vaccines and Immunity, The Research Institute at Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, Ohio
Phillip S. Wozniak

²Center for Perinatal Research, The Research Institute at Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, Ohio
Pablo J. Sánchez

²Center for Perinatal Research, The Research Institute at Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, Ohio

³Division of Neonatology, Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, Ohio

⁴Division of Infectious Diseases, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, Ohio
Octavio Ramilo

¹Center for Vaccines and Immunity, The Research Institute at Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, Ohio

⁴Division of Infectious Diseases, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, Ohio
Asuncion Mejias

¹Center for Vaccines and Immunity, The Research Institute at Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, Ohio

⁴Division of Infectious Diseases, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, Ohio

⁵Departamento de Farmacologia y Pediatria, Facultad de Medicina de Malaga, Universidad de Malaga (UMA), Spain

Abstract

Respiratory syncytial virus (RSV) remains the leading cause for hospitalizations in infants worldwide, resulting in significant health and financial burden. Since 1998, the humanized monoclonal antibody palivizumab remains the only available option licensed for the prevention of severe RSV disease in high-risk children, namely premature infants and those with chronic lung disease and congenital heart disease. In 2014, the American Academy of Pediatrics modified the recommendations on the use of RSV prophylaxis in these high-risk children, and limited its use to premature infants born at < 28 weeks' gestational age (wGA). Following this last guidance update, studies have confirmed that premature infants of 29 to 34 wGA remain at high risk for severe RSV disease, especially those of younger chronologic age. New and more cost-effective strategies are being developed that would help alleviate both the health and financial burden associated with severe RSV disease.

Keywords

respiratory syncytial virus - palivizumab - premature infants - disease severity - hospitalizations

Full Text

References

References
1 Shi T, McAllister DA, O'Brien KL. , et al; RSV Global Epidemiology Network. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet 2017; 390 (10098): 946-958
2 Stockman LJ, Curns AT, Anderson LJ, Fischer-Langley G. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006. Pediatr Infect Dis J 2012; 31 (01) 5-9
3 García CG, Bhore R, Soriano-Fallas A. , et al. Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis. Pediatrics 2010; 126 (06) e1453-e1460
4 Mejias A, Dimo B, Suarez NM. , et al. Whole blood gene expression profiles to assess pathogenesis and disease severity in infants with respiratory syncytial virus infection. PLoS Med 2013; 10 (11) e1001549
5 McLellan JS, Chen M, Leung S. , et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 2013; 340 (6136): 1113-1117
6 Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102 (03) 531-537
7 Feltes TF, Cabalka AK, Meissner HC. , et al; Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143 (04) 532-540
8 Blanken MO, Rovers MM, Molenaar JM. , et al; Dutch RSV Neonatal Network. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med 2013; 368 (19) 1791-1799
9 Rajah B, Sanchez PJ, Garcia-Maurino C, Leber A, Ramilo O, Mejias A. Impact of the updated guidance for palivizumab prophylaxis against respiratory syncytial virus infection: a single center experience. J Pediatr 2017; 181: 183-188
10 Wozniak PS, Sanchez PJ, Rajah B. , et al. Impact of the Revised Guidelines for Respiratory Syncytial Virus Prophylaxis: Morbidity Persists After Two Seasons. Infectious Diseases Society of America 54th Annual Meeting ID Week; 2016; New Orleans, LA.; 2016
11 Anderson EJ, Krilov LR, DeVincenzo JP. , et al. SENTINEL1: an observational study of respiratory syncytial virus hospitalizations among U.S. infants born at 29 to 35 weeks' gestational age not receiving immunoprophylaxis. Am J Perinatol 2017; 34 (01) 51-61
12 Kong AM, Krilov LR, Fergie J. , et al. The 2014-2015 national impact of the 2014 American Academy of Pediatrics guidance for respiratory syncytial virus immunoprophylaxis on preterm infants born in the United States. Am J Perinatol 2018; 35 (02) 192-200
13 Goldstein M, Krilov LR, Fergie J. , et al. Respiratory syncytial virus hospitalizations among U.S. preterm infants compared with term infants before and after the 2014 American Academy of Pediatrics guidance on immunoprophylaxis: 2012-2016. Am J Perinatol 2018; 35 (14) 1433-1442
14 Mejias A, Garcia-Maurino C, Rodriguez-Fernandez R, Peeples ME, Ramilo O. Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection. Vaccine 2017; 35 (03) 496-502
15 Simoes E. Phase 3, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of Suptavumab, for the Prevention of Medically attended RSV Infection in Preterm Infants. 2018 Respiratory Syncytial Virus Symposium; 2018; Ashville, NC.; 2018
16 Domachowske JB, Khan AA, Esser MT. , et al. Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion f-targeting monoclonal antibody administered as a single dose to healthy preterm infants. Pediatr Infect Dis J 2018; 37 (09) 886-892